{
    "nct_id": "NCT04452955",
    "official_title": "An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors",
    "inclusion_criteria": "* Patients with unresectable or metastatic solid tumors willing to provide signed informed consent.\n* Histopathological diagnosis and metastatic status cancer at study entry.\n* Must have received at least 1 prior line of systemic therapy for metastatic disease but no more than 3 prior lines of treatment for metastatic disease.\n* Life expectancy of more than 6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score or less than 2.\n* Adequate organ and hematological function.\n* Measurable disease by RECIST v1.1 and iRECIST.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient has known untreated or symptomatic central nervous system metastasis.\n* Patient is receiving systemic glucocorticoids or other immunosuppressive treatments for autoimmune disease or any other medical condition.\n* Patient has experienced a severe hypersensitivity reaction to another monoclonal antibody.\n* Patient has received treatment with any systemic anti-cancer therapies within 3 weeks prior to starting study treatment.\n* Patient has undergone radiotherapy â‰¤ 4 weeks prior to starting study treatment.\n* Patient has received > 3 lines of prior systemic chemotherapy for metastatic disease",
    "miscellaneous_criteria": ""
}